Integrity Applications Overview
Integrity Applications develops the GlucoTrack model DF-F, a noninvasive blood glucose monitor designed to help people with diabetes obtain blood glucose level measurements without pain. GlucoTrack enables individuals with type-1 and type-2 diabetes to measure their blood glucose levels without drawing blood. A small sensor clips comfortably to the earlobe, while the blood glucose level is calculated using a proprietary algorithm. The results are displayed on a handheld device the size of a smartphone. GlucoTrack removes the two most significant barriers to frequent monitoring of blood glucose levels by diabetics: pain (the device is noninvasive) and cost (no disposables are required).
Cumulative Funding Raised Over Time ($)
$1.1MApr 2016
$13.1MAug 2017
$16.7MDec 2010
$25.2MJan 2015
$25.2MMar 2010
$32.7MMar 2013
$35.7MSep 2014
Latest News
growth-positive
Integrity Applications Provides Commercial Update
Integrity Applications, Inc. has provided an update on its commercialization activities for GlucoTrack, a non-invasive device for measuring glucose levels. The company has received CE Mark approval to simplify the use of GlucoTrack, allowing users to perform the calibration process themselves. The company has completed testing and internal trials of upgraded software and a redesigned personal ear clip. It has also shipped the redesigned units and software upgrade to its distribution partner, MediReva, in the Netherlands. Field testing will be conducted before GlucoTrack is made available to the public early next year. The company is also working with insurance companies for reimbursement approval. The company plans to identify and negotiate with additional distributors in other regions. The market eagerly awaits the solution that GlucoTrack provides for glucose self-monitoring among patients with Type 2 diabetes and prediabetes.
PartnersCustomers
growth-positive
Integrity Applications Expands and Strengthens Team with Appointment of Erez Ben-Zvi as Vice President of Product
Integrity Applications, Inc. has announced the appointment of Erez Ben-Zvi as Vice President of Product. Ben-Zvi brings 15 years of product management and leadership experience in the medical device industry. His role will involve scaling the GlucoTrack product offering and leading the companys global product development. GlucoTrack is a non-invasive device for measuring glucose levels in people with Type 2 diabetes and prediabetes. The appointment reflects Integritys commitment to leadership in the commercialization and growth of GlucoTrack. Ben-Zvi expressed excitement about joining the Integrity team and executing the companys vision to give patients more control over their care.
Expand
growth-positive
Integrity Applications Announces the Appointment of Yair Briman as Senior Executive Advisor
Integrity Applications, Inc. has announced that Yair Briman has joined the company as a Senior Executive Advisor. Briman brings significant commercial, operational, and business development leadership to the company. He has over 20 years of global leadership experience in the digital healthcare industry and has served in various senior executive roles at Philips Healthcare. Brimans insights will be critical as Integrity Applications continues to build GlucoTrack and its digital health platform into a market leader in the management of Type 2 diabetes and prediabetes. GlucoTrack is a non-invasive monitoring device that rapidly measures and displays an individuals glucose level without finger pricking or pain. The device has received approvals for CE Mark in Europe and from the Ministry of Food and Drug Safety in South Korea.
Management Changes
Integrity Applications Announces the Appointment of David Malka as President
Integrity Applications Announces the Appointment of Allen E. Danzig to its Board of Directors and as Chair of the Nominating, Governance and Compensation Committee
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $50.69M |
| Last funding | $15M |
| Stage | Public |
| Rounds | 9 |
| Investors | 1 |
Team Members
4
Employees: 1-10
Web & Social Links
| Website | www.integrity-app.com |
Locations
Ha-Yahalomim St 19, Ashdod, Israel
Photos & Videos
3 item(s)
Integrity Applications Business
Business models
B2B2C
Product stage
Released
Employees
1-10
Sector
Health Tech & Life SciencesMedical DevicesMedical MonitorsDigital HealthcarePatient Remote MonitoringTarget Customer
Healthcare & Life SciencesHealthcarePatientsProvidersCommerce & RetailDistribution ChannelsDistributorCore Technology
Platforms & InterfacesSoftwareSensingTags (15)
non-invasivemeasurementshome-careremote-monitoringsensorsmedical-devicesdiabetesdigital-healthcaremonitoringchronic-patientsoptronicssoftware-applicationsalgorithmsmedical-technologieswearableGeographic Markets
ChinaSaudi ArabiaEuropeHong KongUnited Arab EmiratesIntegrity Applications Financials
$50.69M
Total funding
Undisclosed
Capital raised
$15M
Last funding
Public
Funding stage
9
Total rounds
1
Investors
Cumulative Funding Raised Over Time ($)
$1.1MApr 2016
$13.1MAug 2017
$16.7MDec 2010
$25.2MJan 2015
$25.2MMar 2010
$32.7MMar 2013
$35.7MSep 2014
Private Equity Funding
Undisclosed Round
Aug 2017
$12M
Andrew Garrett
Undisclosed Round
Apr 2016
$1.13M
Undisclosed Round
Jan 2015
$8.5M
Undisclosed Round
Sep 2014
$3.04M
Undisclosed Round
Mar 2013
$7.46M
Undisclosed Round
Dec 2010
$3.57M
Debt Financing
Mar 2010
$50K
Public Offering / Exit
POEvent
Feb 2020
Undisclosed
POEvent
Nov 2011
Undisclosed
Integrity Applications Lifecycle
Cumulative Funding Raised Over Time
$1.1MApr 2016
$13.1MAug 2017
$16.7MDec 2010
$25.2MJan 2015
$25.2MMar 2010
$32.7MMar 2013
$35.7MSep 2014
All Events
Undisclosed Round
Aug 2017
$12M
Andrew Garrett
Undisclosed Round
Apr 2016
$1.13M
Undisclosed Round
Jan 2015
$8.5M
Undisclosed Round
Sep 2014
$3.04M
Undisclosed Round
Mar 2013
$7.46M
Undisclosed Round
Dec 2010
$3.57M
Debt Financing
Mar 2010
$50K
POEvent
Feb 2020
Undisclosed
POEvent
Nov 2011
Undisclosed
Integrity Applications News
15 articles
growth-positive
Integrity Applications Provides Commercial Update
Integrity Applications, Inc. has provided an update on its commercialization activities for GlucoTrack, a non-invasive device for measuring glucose levels. The company has received CE Mark approval to simplify the use of GlucoTrack, allowing users to perform the calibration process themselves. The company has completed testing and internal trials of upgraded software and a redesigned personal ear clip. It has also shipped the redesigned units and software upgrade to its distribution partner, MediReva, in the Netherlands. Field testing will be conducted before GlucoTrack is made available to the public early next year. The company is also working with insurance companies for reimbursement approval. The company plans to identify and negotiate with additional distributors in other regions. The market eagerly awaits the solution that GlucoTrack provides for glucose self-monitoring among patients with Type 2 diabetes and prediabetes.
PartnersCustomers
growth-positive
Integrity Applications Expands and Strengthens Team with Appointment of Erez Ben-Zvi as Vice President of Product
Integrity Applications, Inc. has announced the appointment of Erez Ben-Zvi as Vice President of Product. Ben-Zvi brings 15 years of product management and leadership experience in the medical device industry. His role will involve scaling the GlucoTrack product offering and leading the companys global product development. GlucoTrack is a non-invasive device for measuring glucose levels in people with Type 2 diabetes and prediabetes. The appointment reflects Integritys commitment to leadership in the commercialization and growth of GlucoTrack. Ben-Zvi expressed excitement about joining the Integrity team and executing the companys vision to give patients more control over their care.
Expand
growth-positive
Integrity Applications Announces the Appointment of Yair Briman as Senior Executive Advisor
Integrity Applications, Inc. has announced that Yair Briman has joined the company as a Senior Executive Advisor. Briman brings significant commercial, operational, and business development leadership to the company. He has over 20 years of global leadership experience in the digital healthcare industry and has served in various senior executive roles at Philips Healthcare. Brimans insights will be critical as Integrity Applications continues to build GlucoTrack and its digital health platform into a market leader in the management of Type 2 diabetes and prediabetes. GlucoTrack is a non-invasive monitoring device that rapidly measures and displays an individuals glucose level without finger pricking or pain. The device has received approvals for CE Mark in Europe and from the Ministry of Food and Drug Safety in South Korea.
Management Changes
Integrity Applications Announces the Appointment of David Malka as President
Integrity Applications Announces the Appointment of Allen E. Danzig to its Board of Directors and as Chair of the Nominating, Governance and Compensation Committee
Integrity Applications Announces the Appointment of Robert T. Guest as Senior Advisor
growth-positive
Integrity Applications Announces GlucoTrack® Customer Experience Program in the Netherlands
Integrity Applications, Inc. has launched a Customer Experience Program in the Netherlands with its distributor MediReva and clinical thought leaders in diabetes care. The program aims to demonstrate the real-world patient and healthcare professional experience with GlucoTrack, a non-invasive device for measuring glucose levels in people with type 2 diabetes and pre-diabetes. The program will be rolled out in two groups of 30 patients and will involve interactions between patients and healthcare providers over a 2-week period. The goal is to accelerate commercialization and the reimbursement process in the Netherlands. The program is expected to expand the market for GlucoTrack in the country and improve the quality of life for patients with type 2 diabetes.
Customers
growth-positive
Integrity Applications Announces GlucoTrack® Product Milestones
Integrity Applications, Inc. has achieved several product development milestones, including receiving CE approval for its GlucoTrack® Link wireless module. The module is an important enhancement to the GlucoTrack® system, offering a fully integrated solution for diabetes management. The GlucoTrack® system is now compliant with the IEC 60601-1-2 standard and has passed the renewal audit for CE Marking. These milestones will accelerate the commercialization of GlucoTrack® in Europe. GlucoTrack® is a non-invasive device that measures glucose levels in people with type 2 diabetes and pre-diabetes without the need for finger pricking. The device has received CE Mark approval in Europe and is available in selected markets in Europe and Asia.
Customers
growth-negative
Integrity Applications Announces Executive Leadership Changes
John Graham has resigned as CEO and chairman of Integrity Applications, Inc. for personal reasons. David Podwalski, the companys previous chief commercial officer, has been appointed as president and chief operations officer. Podwalski has over 20 years of experience in global commercial leadership. Integrity Applications is the innovator of GlucoTrack, a non-invasive device for measuring glucose levels in people with type 2 diabetes and pre-diabetes. The company is focused on the design, development, and commercialization of non-invasive glucose monitoring technologies. GlucoTrack has received approvals for CE Mark in Europe and from the Ministry of Food and Drug Safety in South Korea. The company is currently in the early stages of commercialization in Europe, South Korea, and other geographies.
Management Changes
growth-positive
https://markets.businessinsider.com/news/stocks/integrity-applications-receives-first-order-from-curatec-nordic-for-glucotrack-1027457681
Integrity Applications, Inc. has received its first order from CuraTec Nordic, its exclusive distributor for the Nordic Countries, for its non-invasive glucose monitoring device, GlucoTrack. The initial order of 100 units will be used to initiate discussions with key stakeholders in Denmark, Sweden, Norway, and Finland. The company is encouraged by the progress being made with CuraTec Nordic and believes that the partnership will allow diabetics and pre-diabetics in the Scandinavian markets to benefit from GlucoTrack. The commercialization of GlucoTrack in Europe is one of Integritys near-term priorities.
Customers
growth-positive
Integrity Applications Incorporated, a Portfolio Company of Arlington Capital, Announces the Acquisition of DGS
Integrity Applications Incorporated (IAI), a portfolio company of Arlington Capital Partners, has announced the acquisition of Dependable Global Solutions (DGS), a provider of cybersecurity and counterintelligence solutions to intelligence and defense customers in the federal government. The acquisition will see DGSs management team join IAIs leadership. The acquisition is the first of many investments aimed at expanding IAIs capabilities and employee base, which will now exceed 1,100.
AcquisitionExpand
growth-positive
Integrity Applications Signs Distribution Agreement for Its GlucoTrack® Glucose Monitoring Device in the Nordic Countries
Integrity Applications, Inc. has entered into an exclusive distribution agreement with CuraTec Nordic, a Scandinavian medical device distributor. The agreement will open sales channels in Denmark, Sweden, Finland, and Norway for GlucoTrack®, the companys non-invasive glucose monitor for people with type 2 diabetes and pre-diabetes. The agreement is seen as a milestone in the companys path to commercializing GlucoTrack®. The Nordic countries represent an important next step in the companys commercialization across Europe. The CEO of CuraTec Nordic expressed excitement about introducing GlucoTrack® to the marketplace. Integrity Applications believes that CuraTec Nordic is the ideal partner to manage sales execution and customer support for GlucoTrack® in the Nordic countries.
Customers
growth-positive
Integrity Applications Signs Distribution Agreement for Its GlucoTrack® Non-Invasive Glucose Monitoring Device in the Netherlands
Integrity Applications, Inc. has entered into an exclusive distribution agreement with MediReva B.V. for the GlucoTrack® in the Netherlands. This agreement is a major milestone for Integrity in commercializing GlucoTrack® and represents an important first program in their updated commercial partnering strategy. MediReva, a leading home care support company in the Netherlands, will be responsible for the distribution of GlucoTrack® and has committed substantial resources to the agreement. The Netherlands is an important market for Integrity, as it serves as a blueprint for other European markets with a high prevalence of diabetes. GlucoTrack® is a non-invasive monitoring device for measuring glucose levels in people with type 2 diabetes and pre-diabetes.
Customers
growth-positive
Integrity Applications Announces Close of $12 Million Private Placement
Integrity Applications, Inc. has successfully closed a private placement offering, raising approximately $12 million over the past 16 months. The investment will support the companys progress towards a non-invasive solution to glucose measurement and the commercialization of GlucoTrack in Europe. The company has raised a total of $35 million in equity financings exclusively through Andrew Garrett. GlucoTrack is a non-invasive monitoring device for measuring glucose levels in people with type 2 diabetes and pre-diabetes. It has received CE Mark and KFDA approvals and is currently in the early stages of commercialization in Europe and South Korea. Clinical trials for FDA approval in the United States are expected to begin in late 2017.
Investment
growth-positive
Integrity Applications Presents Data Demonstrating that the Accuracy of GlucoTrack® Is Independent of Medication Regime at American Diabetes Association's 77th Scientific Sessions
Integrity Applications, Inc. announced new data demonstrating the clinical performance of GlucoTrack, a non-invasive device for measuring glucose levels in people with type 2 diabetes. The study evaluated GlucoTracks accuracy in 172 adults with type 2 diabetes who were prescribed one or more medications for major medical conditions associated with diabetes. The results showed that GlucoTrack provides accurate non-invasive glucose measurements independent of different medication regimes. This supports the companys commitment to developing an accurate and non-invasive glucose monitoring device suitable for people with type 2 diabetes. GlucoTrack has received CE Mark and KFDA approvals and is currently in the early stages of commercialization in Europe, South Korea, and other geographies. Clinical trials for United States FDA approval are expected to begin in late 2017.
Customers
Integrity Applications Team
Employee Info
| Employees (range) | 1-10 |
| Exact count | 5 |
| Team members | 4 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 15 classification IDs that could be used for matching.
Integrity Applications Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 100/100 |
| Missing | markets |
| BI Verification | Yanina Wainscheinker |
| Registrar ID | 513151878 |
| Crunchbase | integrity-applications |
| Phone | +97286757878 |
| Creator | Rebecca Mack |
| Creator email | rebeccamack26@gmail.com |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wain@gmail.com |
| Last update | 2020-10-08T00:00:00.000Z |
| Created | 2014-06-23T00:00:00.000Z |
| Claimed | Yes |
| Hidden | The company ceased operations in Israel (visible: 0) |
| Status detail | Public on OTC on Nov, 2011<br> |